Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VEGFA | P15692 | 11/20 | 0.83 |
| ▸ | EGLN1 | Q9GZT9 | 11/20 | 0.83 |
| ▸ | DRD4 | P21917 | 3/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | DRD2 | P14416 | 1/20 | 0.50 |
| ▸ | DRD3 | P35462 | 1/20 | 0.50 |
| ▸ | HTR7 | P34969 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL278202 | 0.91 | VEGFA (1.00) | VEGFAEGLN1KDM4EALDH1A1HTT | |
| SCHEMBL273037 | 0.87 | EGLN1 (0.87) | VEGFAEGLN1KDM4EALDH1A1HTT | |
| SCHEMBL272504 | 0.86 | VEGFA (0.62) | VEGFAEGLN1TSHRKDM4EALDH1A1 | |
| SCHEMBL272666 | 0.86 | VEGFA (0.81) | VEGFAEGLN1KDM4EALDH1A1HTT | |
| SCHEMBL272116 | 0.86 | VEGFA (0.85) | VEGFAEGLN1KDM4EALDH1A1HTT | |
| SCHEMBL272076 | 0.86 | VEGFA (0.85) | VEGFAEGLN1KDM4EALDH1A1HTT | |
| SCHEMBL273696 | 0.86 | EGLN1 (0.85) | VEGFAEGLN1KDM4EHTT | |
| SCHEMBL271963 | 0.86 | EGLN1 (0.85) | VEGFAEGLN1KDM4EHTT | |
| SCHEMBL277668 | 0.86 | EGLN1 (0.85) | VEGFAEGLN1KDM4EHTT | |
| SCHEMBL20763926 | 0.85 | VEGFA (0.83) | VEGFAEGLN1TSHRKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8133894-B2 | N-benzyl-4-methyleneamino-3-hydroxy-2-pyridones | AKEBIA THERAPEUTICS INC. (US) | 2012-03-13 | — | — | US | claimed |
| US-20100305097-A1 | N-BENZYL-4-METHYLENEAMINO-3-HYDROXY-2-PYRIDONES | WARNER CHILCOTT COMPANY, LLC | 2010-12-02 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305097-A1 | N-BENZYL-4-METHYLENEAMINO-3-HYDROXY-2-PYRIDONES | IL17A, IFNG, CD4 | VEGFA 3152/4885EGLN1 776/4885DRD4 2254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.